This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Celecoxib to Prevent Cancer in Patients With Barrett's Esophagus

This study has been completed.
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Sidney Kimmel Comprehensive Cancer Center Identifier:
First received: June 2, 2000
Last updated: October 12, 2016
Last verified: October 2016

RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. Celecoxib may be effective in preventing cancer in patients with Barrett's esophagus.

PURPOSE: Randomized phase II trial to study the effectiveness of celecoxib in preventing cancer in patients who have Barrett's esophagus.

Condition Intervention Phase
Esophageal Cancer Drug: celecoxib Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Masking: Double
Primary Purpose: Prevention
Official Title: Chemoprevention for Barrett's Esophagus Trial (CBET)

Resource links provided by NLM:

Further study details as provided by Sidney Kimmel Comprehensive Cancer Center:

Study Start Date: July 2000
Study Completion Date: September 2005
Primary Completion Date: September 2005 (Final data collection date for primary outcome measure)
Detailed Description:


  • Determine the safety and efficacy of celecoxib for regression of Barrett's dysplasia in patients with low or high-grade dysplasia of the esophagus.

OUTLINE: This is a randomized, parallel, double-blind, placebo-controlled, multicenter study. Patients are stratified according to center and grade of dysplasia at baseline (low vs high). Patients are randomized to one of two treatment arms.

  • Arm I: Patients receive oral celecoxib twice daily for 48-96 weeks.
  • Arm II: Patients receive oral placebo as in arm I. Treatment continues in both arms in the absence of unacceptable toxicity or development of adenocarcinoma of the esophagus or cancer at other sites.

Patients are followed at 12 weeks.

PROJECTED ACCRUAL: A total of 200 patients (100 per arm) will be accrued for this study.


Ages Eligible for Study:   18 Years to 120 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No


  • Histologically confirmed Barrett's dysplasia with specific information on the location (level) of the highest grade of dysplasia based on biopsy from baseline endoscopy

    • Short segment Barrett's esophagus must be sufficient area to allow for biopsy without complete resection
  • No presence of reflux esophagitis grades 2-4
  • No history of confirmed invasive carcinoma of the esophagus
  • No diagnosis of esophageal, gastric, pyloric channel, or duodenal ulceration of 1 cm or more in diameter within the past 30 days



  • 18 and over

Performance status:

  • ECOG 0-2

Life expectancy:

  • Not specified


  • Hemoglobin at least 9 g/dL
  • Platelet count greater than 125,000/mm^3
  • WBC greater than 3,000/mm^3
  • No significant bleeding disorder
  • No other abnormal hematopoietic laboratory test result that would preclude study


  • PT/PTT no greater than 1.5 times upper limit of normal (ULN)
  • AST/ALT less than 1.5 times ULN
  • Alkaline phosphatase less than 1.5 times ULN
  • No chronic or acute hepatic disorder
  • No abnormal hepatic laboratory test result that would preclude study


  • Creatinine no greater than 1.5 times ULN
  • No chronic or acute renal disorder
  • No other abnormal renal laboratory test result that would preclude study


  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception
  • No prior or concurrent active inflammatory bowel disease (e.g., Crohn's disease or ulcerative colitis)
  • No other prior or concurrent curatively treated malignancy with a survival prognosis of less than 5 years
  • No hypersensitivity or adverse reaction to COX-2 inhibitors (e.g., celecoxib), sulfonamides, salicylates, or NSAIDs
  • No other significant medical, psychological, or psychosocial condition that would preclude study participation


Biologic therapy:

  • Not specified


  • Not specified

Endocrine therapy:

  • At least 6 months since prior regular (at least 2 weeks duration) oral or intravenous corticosteroids
  • At least 6 months since prior regular (at least 4 weeks duration) inhaled corticosteroids
  • No concurrent regular oral or intravenous corticosteroids
  • No concurrent regular inhaled corticosteroids
  • Concurrent corticosteroid nasal spray allowed


  • At least 12 weeks since prior radiotherapy to the chest or upper abdomen


  • At least 3 months since prior surgery to the esophagus or stomach except hiatal hernia repair, fundoplication, vagotomy, or pyloroplasty
  • No prior complete mucosal resection using any technique
  • No concurrent resection of high-grade nodule


  • At least 30 days since prior chronic (at least 3 times a week for greater than 2 weeks) aspirin or other nonsteroidal antiinflammatory drugs (NSAIDs) (i.e., greater than 100 mg/day)
  • No prior complete mucosal ablation using any technique
  • No prior treatment on this study
  • At least 30 days since prior investigational medication including shingles vaccine
  • No concurrent chronic NSAIDs or COX-2 inhibitors except low-dose aspirin (i.e., no greater than 100 mg/day)
  • No concurrent anticoagulants (e.g., heparin or warfarin)
  • No other concurrent investigational medication
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00005878

United States, Arizona
Veterans Affairs Medical Center - Tucson
Tucson, Arizona, United States, 85723
United States, California
Jonsson Comprehensive Cancer Center, UCLA
Los Angeles, California, United States, 90095-1781
United States, Illinois
Veterans Affairs Medical Center - Hines (Hines Junior VA Hospital)
Hines, Illinois, United States, 60141
United States, Maryland
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland, United States, 21231-2410
United States, Minnesota
Mayo Clinic Cancer Center
Rochester, Minnesota, United States, 55905
United States, New York
Herbert Irving Comprehensive Cancer Center
New York, New York, United States, 10032
United States, Ohio
Ireland Cancer Center
Cleveland, Ohio, United States, 44106
United States, Oregon
Veterans Affairs Medical Center - Portland
Portland, Oregon, United States, 97207
Sponsors and Collaborators
Sidney Kimmel Comprehensive Cancer Center
National Cancer Institute (NCI)
Study Chair: Arlene A. Forastiere, MD Sidney Kimmel Comprehensive Cancer Center
  More Information

Responsible Party: Sidney Kimmel Comprehensive Cancer Center Identifier: NCT00005878     History of Changes
Other Study ID Numbers: JHOC-J9932, CDR0000067917
P30CA006973 ( U.S. NIH Grant/Contract )
Study First Received: June 2, 2000
Last Updated: October 12, 2016

Keywords provided by Sidney Kimmel Comprehensive Cancer Center:
esophageal cancer

Additional relevant MeSH terms:
Esophageal Neoplasms
Barrett Esophagus
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Head and Neck Neoplasms
Digestive System Diseases
Esophageal Diseases
Gastrointestinal Diseases
Digestive System Abnormalities
Cyclooxygenase 2 Inhibitors
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents processed this record on August 21, 2017